Key Points
- CEO Martine Rothblatt sold 9,500 shares on March 13 at an average of $538, totaling about $5.11 million, leaving her with 130 shares (a 98.65% reduction in her holding).
- United Therapeutics reported Q4 EPS of $7.70 (beating the $6.78 estimate) but revenue of $790.2M missed estimates; the company posted strong profitability (net margin ~41.9%) and has a market cap of about $23.25 billion.
- Analysts are generally positive—nine Buys and three Holds—with an average target of about $548.09 and several firms (UBS, RBC, TD Cowen, Cantor Fitzgerald) recently raising targets or reiterating bullish ratings.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, March 13th. The shares were sold at an average price of $538.00, for a total value of $5,111,000.00. Following the completion of the sale, the chief executive officer directly owned 130 shares in the company, valued at approximately $69,940. This represents a 98.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
United Therapeutics Stock Performance
United Therapeutics stock opened at $530.35 on Thursday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $548.12. The stock has a market capitalization of $23.25 billion, a P/E ratio of 19.01, a price-to-earnings-growth ratio of 1.94 and a beta of 0.84. The stock has a fifty day moving average of $488.85 and a 200-day moving average of $465.99.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period last year, the firm posted $6.19 earnings per share. United Therapeutics's revenue was up 7.4% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Clearstead Advisors LLC raised its holdings in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after buying an additional 23 shares during the last quarter. Independent Advisor Alliance grew its holdings in shares of United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock valued at $406,000 after buying an additional 27 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock valued at $472,000 after buying an additional 28 shares during the last quarter. Florida Financial Advisors LLC increased its position in shares of United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company's stock worth $268,000 after acquiring an additional 28 shares in the last quarter. Finally, NDVR Inc. raised its holdings in shares of United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company's stock worth $300,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
Wall Street Analysts Forecast Growth
UTHR has been the topic of a number of research analyst reports. UBS Group raised their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a research note on Thursday, March 5th. Bank of America reissued a "neutral" rating on shares of United Therapeutics in a research note on Wednesday, February 25th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. TD Cowen boosted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Finally, Cantor Fitzgerald upped their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a report on Thursday, March 12th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $548.09.
Read Our Latest Research Report on UTHR
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
